DTIL Key Statistics, Chart & Performance
The current stock price of DTIL is 3.92 USD. In the past month the price decreased by -21.76%. In the past year, price decreased by -31.23%.
DTIL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About DTIL
Company Profile
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 67 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.
Company Info
PRECISION BIOSCIENCES INC
302 E Pettigrew St Ste A100
Durham NORTH CAROLINA 27701 US
CEO: Matthew Kane
Employees: 67
Phone: 19193145512
PRECISION BIOSCIENCES INC / DTIL FAQ
Can you describe the business of PRECISION BIOSCIENCES INC?
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 67 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.
Can you provide the latest stock price for PRECISION BIOSCIENCES INC?
The current stock price of DTIL is 3.92 USD. The price decreased by -2.73% in the last trading session.
Does PRECISION BIOSCIENCES INC pay dividends?
DTIL does not pay a dividend.
What is the ChartMill technical and fundamental rating of DTIL stock?
DTIL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of DTIL stock?
PRECISION BIOSCIENCES INC (DTIL) operates in the Health Care sector and the Biotechnology industry.
What is the Short Interest ratio of PRECISION BIOSCIENCES INC (DTIL) stock?
The outstanding short interest for PRECISION BIOSCIENCES INC (DTIL) is 3.79% of its float.
DTIL Technical Analysis
DTIL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to DTIL. DTIL has a bad profitability rating. Also its financial health evaluation is rather negative.
DTIL Financial Highlights
Over the last trailing twelve months DTIL reported a non-GAAP Earnings per Share(EPS) of -8.4. The EPS decreased by -322.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.4% | ||
| ROE | -502.6% | ||
| Debt/Equity | 1.35 |
DTIL Forecast & Estimates
10 analysts have analysed DTIL and the average price target is 33.15 USD. This implies a price increase of 745.66% is expected in the next year compared to the current price of 3.92.
For the next year, analysts expect an EPS growth of -4071.8% and a revenue growth -87.36% for DTIL